Opioid pharmacotherapy: Treatment, regimes, constructions and control

Neale, Joanne

doi:10.1016/j.drugpo.2013.08.003

Cited by 16 publications

(14 citation statements)

References 270 publications

(359 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, this would in turn enable them to pursue 'constructive', non-drug using lives characterised by reduced stigma and increased 'normality', 'freedom', and flexibility. Participants' high expectations of depot buprenorphine stand in stark contrast to patients' widely-reported criticisms of the inconvenience, stigma, restrictions and burden of taking oral OAT every day (Crawford, 2013;Fraser & valentine, 2008;Harris & McElrath, 2012;Neale, 2013;Neale et al, 2018b;Radcliffe & Parkes, 2013;Strike et al, 2013). Whilst this suggests that depot buprenorphine could potentially overcome key limitations of traditional OAT formulations, people may have unrealistic beliefs about, and hopes for, new medicinal products, particularly if they have not yet experienced the treatment and yet are eager for treatment or want a rapid solution to complex problems.…”

Section: Discussionmentioning

confidence: 99%

“…Despite this, drugs such as methadone and buprenorphine have known negative side effects which include physical dependence (Brunton, Knollmann, & Hilal-Dandan, 2017;Itzoe & Guarnieri, 2017). In some countries, OAT remains controversial, politically divisive and disliked, even amongst people who use it (Neale, 2013). This constitutes a major obstacle in the treatment of OUD given that uptake and adherence are both likely to be poor if patients have negative views and expectations about the medications being offered to them.…”

Section: Introductionmentioning

confidence: 99%

“…Some people prescribed oral methadone have repeatedly described it as a stigmatizing, restrictive and punitive treatment (Crawford, 2013;Harris & McElrath, 2012;Radcliffe & Parkes, 2013;Strike, Millson, Hopkins, & Smith, 2013). Indeed, patients have likened it to a form of social control because it can tie them to strict medication-related rules and monitoring systems, such as urinalysis and daily attendance at services (Chandler et al, 2013;Crawford, 2013;Neale, 2013;Strike et al, 2013;Treloar & valentine, 2013). Studies have compared patients' views of oral methadone with oral buprenorphine (Hill et al, 2015;Kelly et al, 2012;Schwartz et al, 2008;White et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder

Tompkins

Neale

Strang

2019

Journal of Substance Abuse Treatment

Self Cite

View full text Add to dashboard Cite

A B S T R A C TAims: Prolonged-release implantable and depot injection formulations of buprenorphine are very recent developments in the treatment of opioid use disorder. Such formulations remove the need for daily dosing and provide patients with sustained concentrations of buprenorphine over a period of weeks or months. We explored opioid users' personal willingness to receive prolonged-release buprenorphine depot injections and factors influencing their interest. Methods: The study took place in London during 2018, before depot buprenorphine was licensed for use in Europe. Thirty-six face-to-face, semi-structured qualitative interviews were conducted with people who were: i) using heroin daily and not receiving any treatment for opioid use (n = 12); or ii) prescribed daily oral buprenorphine (n = 12); or iii) prescribed daily oral methadone (n = 12). Participants were asked about their willingness to receive depot buprenorphine and were encouraged to discuss factors that might alter their opinions. Interview data were analysed following the stages of Iterative Categorization. Findings: Participants expressed a high level of willingness to receive depot buprenorphine. Their views were influenced both positively and negatively by six key features of depot buprenorphine: i) reduced contact with pharmacies and drug treatment services; ii) impact on illicit drug use and recovery; iii) the perceived effectiveness of depot buprenorphine; iv) the duration and dosage of depot buprenorphine injections; v) clinical administration of the depot buprenorphine injection; and vi) potential for side effects associated with the depot buprenorphine injection. Conclusions: Willingness to receive a given medication is complex, individual and changeable. Opioid users seem likely to welcome greater choice and flexibility in respect of opioid agonist medications and appear more likely to accept and adhere to depot buprenorphine if it enables them to reduce their illicit drug use and facilitates their recovery. Research is now needed to assess whether patients' reported willingness to receive depot buprenorphine translates into actual uptake and adherence. (Clinical Guidelines on Drug Misuse and Dependence (Update), 2017).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder

Tompkins

Neale

Strang

2019

Journal of Substance Abuse Treatment

Self Cite

View full text Add to dashboard Cite

show abstract

“…Harris & McElrath, 2012). Many PWID considered methadone to be halfway between drug and medication (Langlois, 2013;Malvini Redden et al, 2013;Neale, 2013). As a drug, it could be purchased on the black market to replace heroin and sometimes to procure pleasure.…”

Section: Factors Influencing Retention In Methadone Treatmentmentioning

confidence: 99%

Struggling to achieve a ‘normal life’: A qualitative study of Vietnamese methadone patients

Nguyen

Luong

Nham

et al. 2019

International Journal of Drug Policy

View full text Add to dashboard Cite

“…Methadone, a pharmacological agent used as a substitute treatment for illicit opioids, has proven to be effective in the treatment of opioid dependence 19,20. Furthermore, it can bring about positive social changes; for instance, reduction in crime rates and in the risk for transmission of blood-borne viruses such as HIV and hepatitis C. However, research has shown that its efficacy and intended positive social effects are not predetermined but are dependent on the sociocultural contexts of the methadone treatment.…”

Section: Introductionmentioning

confidence: 99%

Examining the relationship between ethnicity and the use of drug-related services: an ethnographic study of Nepali drug users in Hong Kong

Tang

2014

SAR

View full text Add to dashboard Cite

A recent survey has shown that Nepali drug users in Hong Kong tend to have a low rate of usage of day-care and residential rehabilitation services, but a high rate of usage of methadone services. Little is known about the reasons behind such a pattern. Therefore, in this study, a 12-month ethnographic examination has been implemented in three sites, including a day-care center, residential rehabilitation center, and methadone clinic, to explore the experiences of 20 Nepali drug users in their use of drug-related services in Hong Kong and to examine the relationship between ethnicity and the use of drug-related services. The result shows that the reason for this pattern of service use is related to the approach of the services and the cultural perception of the service providers about the service users. The day-care and residential rehabilitation services emphasize an integrated approach, but the staff tend to overlook the heterogeneity of their clients, for example, the differences in caste and sex, and fail to provide suitable services to them, whereas the methadone service follows a biomedical model, which seldom addresses the social characteristics of the service users, which in turn minimizes the opportunity for misunderstandings between the staff and the clients. This research shows that ethnicity is a significant factor in drug treatment and that culture-specific treatment that takes into consideration the treatment approach and the heterogeneity of the clients is strongly needed.

show abstract

Opioid pharmacotherapy: Treatment, regimes, constructions and control

Cited by 16 publications

References 270 publications

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder

Struggling to achieve a ‘normal life’: A qualitative study of Vietnamese methadone patients

Examining the relationship between ethnicity and the use of drug-related services: an ethnographic study of Nepali drug users in Hong Kong

Contact Info

Product

Resources

About